Physician profile
Lance D Dubberke
NPI 1871690115
$2,456.04
in general payments reported to CMS, 2019-2025
25 companies · $379 in 2025
The $379 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $453 · 2020: $222 · 2021: $203 · 2022: $340 · 2023: $359 · 2024: $499 · 2025: $379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,237.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $474.91 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $334.65 | 2022-2025 | Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $328.10 | 2019-2025 | Brilinta, Farxiga, Airsupra |
| Lilly USA, LLC | $212.80 | 2019-2023 | Emgality, Jardiance, Mounjaro |
| Amgen INC. | $204.71 | 2019-2024 | Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.83 | 2020-2025 | Jardiance, Tradjenta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $149.59 | 2019-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $75.55 | 2022-2025 | |
| Glaxosmithkline, LLC. | $61.81 | 2019-2024 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $58.29 | 2019 | |
| Xeris Pharmaceuticals, INC. | $55.59 | 2022-2024 | Keveyis, Gvoke Hypopen |
| Pfizer INC. | $44.80 | 2019-2023 | |
| Mylan Specialty L.P. | $40.54 | 2023-2024 | Yupelri |
| Allergan, INC. | $31.42 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.40 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $26.83 | 2019-2023 | Veozah |
| Amarin Pharma, INC. | $25.08 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $23.90 | 2020-2021 | |
| Verona Pharma, INC. | $23.08 | 2025 | Ohtuvayre |
| Phathom Pharmaceuticals, INC. | $20.09 | 2025 | Voquezna |
| Exact Sciences Corporation | $17.76 | 2025 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $17.48 | 2025 | Auvelity |
| Merck Sharp & Dohme LLC | $15.74 | 2024 | Gardasil 9, Gardasil, Capvaxive |
| Strongbridge US INC. | $14.55 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lance Dubberke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.